Last update June 12, 2018
Antiandrogenic drug that acts by blocking testosterone receptors which is used for treatment of prostate carcinoma.
Not authorized for use in women although it is used for treatment of hirsutism with same or greater efficacy than Spironolactone (Erenus 1994 Cusan 1994, Moghetti 2000), androgenetic alopecia (Paradisi 2011). Also used for treatment of Polycystic Ovary Syndrome (Gambineri 2006).
At latest update no published data on excretion into breast milk were found.
Its high plasma protein-binding capacity makes it unlikely the excretion of significant amounts into breastmilk.
Not alterations on prolactin level have been reported.
Be aware that an aniline-containing metabolite would appear, which can lead under certain circumstances to develop Methemoglobinemia.
A known and safer alternative should be preferred until more published data on this drug related to breastfeeding is available within the first 6 mo after birth, especially during the neonatal period and in case prematurity.
Exposure through breastmilk may be minimized by waiting at least 6 hours before resuming breastfeed after the last dose of drug.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM